Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, China.
Department of Pathology, Children's Hospital of Nanjing Medical University, Nanjing, China.
J Clin Lab Anal. 2023 Mar;37(5):e24866. doi: 10.1002/jcla.24866. Epub 2023 Mar 15.
The cell surface glycoprotein glypican 2 (GPC2) has been shown to increase susceptibility to neuroblastoma, which is the most common malignancy in children. However, associations between single nucleotide polymorphism(s) of GPC2 and neuroblastoma risk remain unclarified.
We conducted a case-control study to investigate two GPC2 polymorphisms (rs1918353 G>A and rs7799441 C>T) in 473 healthy controls and 402 pediatric patients with neuroblastoma. Single nucleotide polymorphism (SNP) genotyping was conducted on the samples by the TaqMan technique, and the data were subsequently analyzed by the t test, chi-squared test, and logistic regression model. In addition, we further performed stratification analysis by age, sex, tumor site of origin, or clinical stage to control confounding factors.
According to the data of dominant models (GA/AA vs. GG: adjusted OR = 0.99, 95% CI = 0.76-1.29, p = 0.943; CT/TT vs. CC: adjusted OR = 0.91, 95% CI = 0.70-1.19, p = 0.498) or other comparisons, as well as the conjoint analysis (adjusted OR = 1.22, 95% CI = 0.93-1.59, p = 0.152), we unfortunately proved that the analysis of single or multiple loci did not support any significant association of GPC2 polymorphisms with susceptibility to neuroblastoma.
GPC2 polymorphisms (rs1918353 G>A and rs7799441 C>T) are unable to statistically affect neuroblastoma risk in Chinese children. Therefore, more samples, especially from patients of various ethnic backgrounds, are required to increase the sample size and verify the effect of GPC2 polymorphisms on neuroblastoma risk in the presence of ethnic factor.
细胞表面糖蛋白聚糖 2（GPC2）已被证明会增加神经母细胞瘤的易感性，神经母细胞瘤是儿童中最常见的恶性肿瘤。然而，GPC2 单核苷酸多态性（SNP）与神经母细胞瘤风险之间的关联仍不清楚。
我们进行了一项病例对照研究，以调查 473 名健康对照者和 402 名患有神经母细胞瘤的儿科患者中的 2 个 GPC2 多态性（rs1918353 G>A 和 rs7799441 C>T）。通过 TaqMan 技术对样本进行 SNP 基因分型，然后通过 t 检验、卡方检验和 logistic 回归模型对数据进行分析。此外，我们还通过年龄、性别、肿瘤起源部位或临床分期进行了分层分析，以控制混杂因素。
根据显性模型（GA/AA 与 GG：调整 OR=0.99，95%CI=0.76-1.29，p=0.943；CT/TT 与 CC：调整 OR=0.91，95%CI=0.70-1.19，p=0.498）或其他比较，以及联合分析（调整 OR=1.22，95%CI=0.93-1.59，p=0.152），我们不幸地证明，单一或多个位点的分析并不支持 GPC2 多态性与神经母细胞瘤易感性之间存在任何显著关联。
GPC2 多态性（rs1918353 G>A 和 rs7799441 C>T）不能从统计学上影响中国儿童的神经母细胞瘤风险。因此，需要更多的样本，特别是来自不同种族背景的患者，以增加样本量，并在存在种族因素的情况下验证 GPC2 多态性对神经母细胞瘤风险的影响。
